The Australian Clinical Labs Ltd (ASX: ACL) share price is tumbling today, but it’s had a whopping run lately.
At the time of writing, the Australian Clinical Labs share price is $5.87. That’s 1.51% lower than its previous close but 38% higher than it was at the end of last month.
Additionally, it reached a new 52-week high in yesterday’s session, hitting $6.39 in intraday trade.
Let’s take a look at what’s been driving the company’s stock lately.
Australian Clinical Labs share price soars in December
Australian Clinical Labs’ stock took off last week after the company upgraded its guidance for the first half of financial year 2022 (FY22).
It now expects to bring in between $497.3 million and $517.2 million of revenue and net profits after tax of $116.3 million to $128 million.
The boosted expectations followed continuous strong demand for COVID-19 testing, particularly in New South Wales and Victoria. The company’s revenue is also being helped along by the resilience of its non-COVID business.
The company’s CEO Melinda McGrath commented on the company’s new outlook, saying:
We anticipate heightened volumes of COVID-19 testing to continue during the remainder of FY22 due to the impact of new variants and outbreaks, the lifting of travel restrictions and increased demand for both commercial and travel testing.
Thus, this week’s case numbers might have brought the stock some extra attention.
Over the 7 days to 8pm last night, New South Wales had reported 52,775 new cases of COVID-19. Of those, 12,226 were recorded in the previous 24 hours.
Victoria also announced a new record number of new daily cases today, with 5,137 of the state’s residents testing positive for the virus.
While the month so far has been a good one for the Australian Clinical Labs share price, today seems to be telling a different story. The company’s stock is tumbling for no obvious reason this morning.
However, despite the slump, it’s still in the long-term green. Right now, the Australian Clinical Labs share price is 72% higher than it was at the start of 2021.
Additionally, it isn’t alone in its recent gains. Fellow pathology companies, Healius Ltd (ASX: HLS) and Sonic Healthcare Limited (ASX: SHL) have seen their share prices increase 13% and 9% respectively this month.
The post What’s going on with the Australian Clinical Labs (ASX:ACL) share price lately? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Australian Clinical Labs right now?
Before you consider Australian Clinical Labs, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Australian Clinical Labs wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
More reading
- Brokers name 3 ASX shares to buy today
- Why Australian Clinical Labs, Magellan, Sandfire, and Telix shares are rising
- Why the Australian Clinical Labs (ASX:ACL) share price is up 10% to a record high
- Why Australian Clinical Labs, Humm, Neometals, and Viva Energy are rising
- Analysts are tipping huge gains for these small cap ASX shares
Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Clinical Labs Limited and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3JuNGD1
Leave a Reply